{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:57:47Z","timestamp":1781564267286,"version":"3.54.5"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early maladaptive schemas seem of importance. Pharmacological treatment includes drugs affecting the serotoninergic, dopaminergic, and glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing that up to 40% of patients with OCD are resistant to the currently available medications, there is a need for novel and effective therapies. Recent discoveries suggest that psilocybin, a non-physically addictive psychoactive substance, may ameliorate disease symptoms. When used in appropriate doses and under strict clinical control, psilocybin appears as a valuable treatment for OCD. This narrative article provides a thorough overview of OCD\u2019s etiology, current treatment options, and the emerging evidence supporting psilocybin\u2019s efficacy in managing OCD symptoms.<\/jats:p>","DOI":"10.1007\/s43440-024-00633-1","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T09:12:56Z","timestamp":1722503576000},"page":"911-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Psilocybin in pharmacotherapy of obsessive-compulsive disorder"],"prefix":"10.1007","volume":"76","author":[{"given":"Maja","family":"Owe-Larsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buchalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Mirowska-Guzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Cudnoch-J\u0119drzejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"633_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/NDT.S403997","volume":"19","author":"I Khan","year":"2023","unstructured":"Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, et al. Use of Selective Alternative therapies for treatment of OCD. Neuropsychiatr Dis Treat. 2023;19:721\u201332.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"633_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-019-0102-3","volume":"5","author":"DJ Stein","year":"2019","unstructured":"Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, et al. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019;5(1):52.","journal-title":"Nat Rev Dis Primers"},{"key":"633_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/7854_2020_195","volume":"49","author":"TU Hauser","year":"2021","unstructured":"Hauser TU. On the development of OCD. Curr Top Behav Neurosci. 2021;49:17\u201330.","journal-title":"Curr Top Behav Neurosci"},{"key":"633_CR4","doi-asserted-by":"crossref","unstructured":"Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A et al. Therapeutic Potential Psilocybin Molecules. 2021;26(10).","DOI":"10.3390\/molecules26102948"},{"key":"633_CR5","doi-asserted-by":"publisher","first-page":"e078084","DOI":"10.1136\/bmj-2023-078084","volume":"385","author":"AM Metaxa","year":"2024","unstructured":"Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084.","journal-title":"BMJ"},{"issue":"11","key":"633_CR6","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.2174\/1570159X21666221017085612","volume":"21","author":"A Mosca","year":"2023","unstructured":"Mosca A, Chiappini S, Miuli A, Mancusi G, Santovito MC, Di Carlo F, et al. Ibogaine\/Noribogaine in the treatment of Substance Use disorders: a systematic review of the current literature. Curr Neuropharmacol. 2023;21(11):2178\u201394.","journal-title":"Curr Neuropharmacol"},{"key":"633_CR7","doi-asserted-by":"publisher","first-page":"120302","DOI":"10.1016\/j.jns.2022.120302","volume":"439","author":"RL Henner","year":"2022","unstructured":"Henner RL, Keshavan MS, Hill KP. Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022;439:120302.","journal-title":"J Neurol Sci"},{"issue":"6","key":"633_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s43440-023-00550-9","volume":"75","author":"A Wojtas","year":"2023","unstructured":"Wojtas A. The possible place for psychedelics in pharmacotherapy of mental disorders. Pharmacol Rep. 2023;75(6):1313\u201325.","journal-title":"Pharmacol Rep"},{"issue":"4\u20136","key":"633_CR9","first-page":"39","volume":"20","author":"WW IsHak","year":"2023","unstructured":"IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J, et al. The impact of psilocybin on patients experiencing Psychiatric symptoms: a systematic review of Randomized clinical trials. Innov Clin Neurosci. 2023;20(4\u20136):39\u201348.","journal-title":"Innov Clin Neurosci"},{"issue":"3","key":"633_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF02159243","volume":"14","author":"A Hofmann","year":"1958","unstructured":"Hofmann A, Heim R, Brack A, Kobel H. [Psilocybin, a psychotropic substance from the Mexican mushroom psilicybe mexicana Heim]. Experientia. 1958;14(3):107\u20139.","journal-title":"Experientia"},{"issue":"2","key":"633_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","volume":"21","author":"D Nutt","year":"2019","unstructured":"Nutt D. Psychedelic drugs-a new era in psychiatry? Dialogues Clin Neurosci. 2019;21(2):139\u201347.","journal-title":"Dialogues Clin Neurosci"},{"issue":"1","key":"633_CR12","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1097\/j.pbj.0000000000000128","volume":"6","author":"H Castro Santos","year":"2021","unstructured":"Castro Santos H, Gama Marques J. What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomed J. 2021;6(1):e128.","journal-title":"Porto Biomed J"},{"issue":"2","key":"633_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE, Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"633_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/02791072.2014.963754","volume":"46","author":"JA Wilcox","year":"2014","unstructured":"Wilcox JA. Psilocybin and obsessive compulsive disorder. J Psychoact Drugs. 2014;46(5):393\u20135.","journal-title":"J Psychoact Drugs"},{"issue":"2","key":"633_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/02791072.2020.1849879","volume":"53","author":"A Lugo-Radillo","year":"2021","unstructured":"Lugo-Radillo A, Md P, Cortes-Lopez JM. Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J Psychoact Drugs. 2021;53(2):146\u20138.","journal-title":"J Psychoact Drugs"},{"issue":"11","key":"633_CR16","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735\u201340.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"633_CR17","doi-asserted-by":"publisher","first-page":"e12135","DOI":"10.1016\/j.heliyon.2022.e12135","volume":"8","author":"B Kelmendi","year":"2022","unstructured":"Kelmendi B, Kichuk SA, DePalmer G, Maloney G, Ching THW, Belser A, et al. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: a case report. Heliyon. 2022;8(12):e12135.","journal-title":"Heliyon"},{"issue":"2","key":"633_CR18","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","volume":"32","author":"B Kelmendi","year":"2022","unstructured":"Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics Curr Biol. 2022;32(2):R63\u20137.","journal-title":"Psychedelics Curr Biol"},{"issue":"4","key":"633_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7(4):357\u201364.","journal-title":"Addict Biol"},{"issue":"10","key":"633_CR20","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1021\/acschemneuro.8b00186","volume":"9","author":"HA Geiger","year":"2018","unstructured":"Geiger HA, Wurst MG, Daniels RN. DARK classics in Chemical Neuroscience: psilocybin. ACS Chem Neurosci. 2018;9(10):2438\u201347.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"633_CR21","doi-asserted-by":"publisher","first-page":"e9019","DOI":"10.1371\/journal.pone.0009019","volume":"5","author":"TS Ray","year":"2010","unstructured":"Ray TS. Psychedelics and the human receptorome. PLoS ONE. 2010;5(2):e9019.","journal-title":"PLoS ONE"},{"issue":"1","key":"633_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/jox12010004","volume":"12","author":"M Coppola","year":"2022","unstructured":"Coppola M, Bevione F, Mondola R. Psilocybin for Treating Psychiatric disorders: a psychonaut legend or a Promising Therapeutic Perspective? J Xenobiot. 2022;12(1):41\u201352.","journal-title":"J Xenobiot"},{"issue":"11","key":"633_CR23","first-page":"e31796","volume":"14","author":"R Irizarry","year":"2022","unstructured":"Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J. Psilocybin as a treatment for Psychiatric illness: a Meta-analysis. Cureus. 2022;14(11):e31796.","journal-title":"Cureus"},{"issue":"10","key":"633_CR24","first-page":"e30214","volume":"14","author":"DB Goel","year":"2022","unstructured":"Goel DB, Zilate S. Potential therapeutic effects of Psilocybin: a systematic review. Cureus. 2022;14(10):e30214.","journal-title":"Cureus"},{"issue":"2","key":"633_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/02791072.2019.1580804","volume":"51","author":"NL Mason","year":"2019","unstructured":"Mason NL, Mischler E, Uthaug MV, Kuypers KPC. Sub-acute effects of Psilocybin on Empathy, Creative thinking, and Subjective Well-Being. J Psychoact Drugs. 2019;51(2):123\u201334.","journal-title":"J Psychoact Drugs"},{"issue":"11","key":"633_CR26","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, Present, and Future. Neuropsychopharmacology. 2017;42(11):2105\u201313.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"633_CR27","first-page":"125","volume":"51","author":"D Latimer","year":"2021","unstructured":"Latimer D, Stocker MD, Sayers K, Green J, Kaye AM, Abd-Elsayed A, et al. MDMA to treat PTSD in adults. Psychopharmacol Bull. 2021;51(3):125\u201349.","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"633_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/2045125316676092","volume":"7","author":"A Mahapatra","year":"2017","unstructured":"Mahapatra A, Gupta R. Role of psilocybin in the treatment of depression. Ther Adv Psychopharmacol. 2017;7(1):54\u20136.","journal-title":"Ther Adv Psychopharmacol"},{"key":"633_CR29","doi-asserted-by":"publisher","first-page":"873279","DOI":"10.3389\/fpsyg.2022.873279","volume":"13","author":"DB Yaden","year":"2022","unstructured":"Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW. Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Front Psychol. 2022;13:873279.","journal-title":"Front Psychol"},{"issue":"5","key":"633_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/02791072.2017.1320734","volume":"49","author":"K Thomas","year":"2017","unstructured":"Thomas K, Malcolm B, Lastra D. Psilocybin-assisted therapy: a review of a Novel Treatment for Psychiatric disorders. J Psychoact Drugs. 2017;49(5):446\u201355.","journal-title":"J Psychoact Drugs"},{"key":"633_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fphar.2018.00733","volume":"9","author":"EE Schenberg","year":"2018","unstructured":"Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in Psychiatric Research and Development. Front Pharmacol. 2018;9:733.","journal-title":"Front Pharmacol"},{"issue":"5","key":"633_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391\u2013410.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"633_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1192\/bjp.bp.111.103309","volume":"200","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012;200(3):238\u201344.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"633_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000348582","volume":"46","author":"MT Williams","year":"2013","unstructured":"Williams MT, Mugno B, Franklin M, Faber S. Symptom dimensions in obsessive-compulsive disorder: phenomenology and treatment outcomes with exposure and ritual prevention. Psychopathology. 2013;46(6):365\u201376.","journal-title":"Psychopathology"},{"issue":"6","key":"633_CR35","doi-asserted-by":"publisher","first-page":"e3000","DOI":"10.1002\/brb3.3000","volume":"13","author":"B Jalal","year":"2023","unstructured":"Jalal B, Chamberlain SR, Sahakian BJ. Obsessive-compulsive disorder: etiology, neuropathology, and cognitive dysfunction. Brain Behav. 2023;13(6):e3000.","journal-title":"Brain Behav"},{"issue":"9330","key":"633_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(02)09620-4","volume":"360","author":"DJ Stein","year":"2002","unstructured":"Stein DJ. Obsessive-compulsive disorder. Lancet. 2002;360(9330):397\u2013405.","journal-title":"Lancet"},{"issue":"1","key":"633_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0165-1781(90)90061-9","volume":"34","author":"SW Kim","year":"1990","unstructured":"Kim SW, Dysken MW, Kuskowski M. The Yale-Brown obsessive-compulsive scale: a reliability and validity study. Psychiatry Res. 1990;34(1):99\u2013106.","journal-title":"Psychiatry Res"},{"key":"633_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jad.2023.05.053","volume":"336","author":"AL Dostal","year":"2023","unstructured":"Dostal AL, Pilkington PD. Early maladaptive schemas and obsessive-compulsive disorder: a systematic review and meta-analysis. J Affect Disord. 2023;336:42\u201351.","journal-title":"J Affect Disord"},{"key":"633_CR39","volume-title":"Schema therapy: a practitioner\u2019s guide","author":"JE Young","year":"2003","unstructured":"Young JE, Klosko JS, Weishaar ME. Schema therapy: a practitioner\u2019s guide. New York: The Guilford Press; 2003."},{"issue":"5","key":"633_CR40","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/YPG.0000000000000230","volume":"29","author":"G Zai","year":"2019","unstructured":"Zai G, Barta C, Cath D, Eapen V, Geller D, Gr\u00fcnblatt E. New insights and perspectives on the genetics of obsessive-compulsive disorder. Psychiatr Genet. 2019;29(5):142\u201351.","journal-title":"Psychiatr Genet"},{"issue":"1","key":"633_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1176\/appi.ajp.2020.20111601","volume":"178","author":"WK Goodman","year":"2021","unstructured":"Goodman WK, Storch EA, Sheth SA. Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. Am J Psychiatry. 2021;178(1):17\u201329.","journal-title":"Am J Psychiatry"},{"key":"633_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/7854_2020_196","volume":"49","author":"BL Chamberlain","year":"2021","unstructured":"Chamberlain BL, Ahmari SE. Animal models for OCD Research. Curr Top Behav Neurosci. 2021;49:55\u201396.","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"633_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12929-023-00925-3","volume":"30","author":"YC Lin","year":"2023","unstructured":"Lin YC, Sahoo BK, Gau SS, Yang RB. The biology of SCUBE. J Biomed Sci. 2023;30(1):33.","journal-title":"J Biomed Sci"},{"issue":"12","key":"633_CR44","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.biopsych.2019.09.029","volume":"87","author":"C Cappi","year":"2020","unstructured":"Cappi C, Oliphant ME, P\u00e9ter Z, Zai G, Concei\u00e7\u00e3o do Ros\u00e1rio M, Sullivan CAW, et al. De Novo damaging DNA coding mutations are Associated with obsessive-compulsive disorder and overlap with Tourette\u2019s disorder and autism. Biol Psychiatry. 2020;87(12):1035\u201344.","journal-title":"Biol Psychiatry"},{"key":"633_CR45","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3389\/fphar.2019.01362","volume":"10","author":"AP Escobar","year":"2019","unstructured":"Escobar AP, Wendland JR, Ch\u00e1vez AE, Moya PR. The neuronal glutamate transporter EAAT3 in obsessive-compulsive disorder. Front Pharmacol. 2019;10:1362.","journal-title":"Front Pharmacol"},{"issue":"3","key":"633_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.neubiorev.2004.11.006","volume":"29","author":"SR Chamberlain","year":"2005","unstructured":"Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev. 2005;29(3):399\u2013419.","journal-title":"Neurosci Biobehav Rev"},{"key":"633_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1875397300802010062","volume":"2","author":"JT Ting","year":"2008","unstructured":"Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics. 2008;2:62\u201375.","journal-title":"Curr Chem Genomics"},{"issue":"1","key":"633_CR48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ijnp\/pyx088","volume":"21","author":"NA Fineberg","year":"2018","unstructured":"Fineberg NA, Apergis-Schoute AM, Vaghi MM, Banca P, Gillan CM, Voon V, et al. Mapping compulsivity in the DSM-5 obsessive compulsive and related disorders: cognitive domains, neural circuitry, and treatment. Int J Neuropsychopharmacol. 2018;21(1):42\u201358.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"633_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tics.2011.11.003","volume":"16","author":"MR Milad","year":"2012","unstructured":"Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43\u201351.","journal-title":"Trends Cogn Sci"},{"issue":"2","key":"633_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/scnp.2001.21833","volume":"6","author":"S Saxena","year":"2001","unstructured":"Saxena S, Bota RG, Brody AL. Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry. 2001;6(2):82\u2013101.","journal-title":"Semin Clin Neuropsychiatry"},{"issue":"3","key":"633_CR51","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1176\/appi.ajp.2013.13040574","volume":"171","author":"SJ de Wit","year":"2014","unstructured":"de Wit SJ, Alonso P, Schweren L, Mataix-Cols D, Lochner C, Mench\u00f3n JM, et al. Multicenter Voxel-based morphometry mega-analysis of structural brain scans in obsessive-compulsive disorder. Am J Psychiatry. 2014;171(3):340\u20139.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"633_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1192\/bjp.bp.115.164020","volume":"210","author":"JP Fouche","year":"2017","unstructured":"Fouche JP, du Plessis S, Hattingh C, Roos A, Lochner C, Soriano-Mas C, et al. Cortical thickness in obsessive-compulsive disorder: multisite mega-analysis of 780 brain scans from six centres. Br J Psychiatry. 2017;210(1):67\u201374.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"633_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1176\/appi.ajp.2016.16020201","volume":"174","author":"PS Boedhoe","year":"2017","unstructured":"Boedhoe PS, Schmaal L, Abe Y, Ameis SH, Arnold PD, Batistuzzo MC, et al. Distinct subcortical volume alterations in Pediatric and Adult OCD: a Worldwide Meta- and Mega-analysis. Am J Psychiatry. 2017;174(1):60\u20139.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"633_CR54","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/npp.2014.5","volume":"39","author":"J Radua","year":"2014","unstructured":"Radua J, Grau M, van den Heuvel OA, Thiebaut de Schotten M, Stein DJ, Canales-Rodr\u00edguez EJ, et al. Multimodal Voxel-based meta-analysis of white matter abnormalities in obsessive-compulsive disorder. Neuropsychopharmacology. 2014;39(7):1547\u201357.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"633_CR55","first-page":"405","volume":"33","author":"JY Rotge","year":"2008","unstructured":"Rotge JY, Guehl D, Dilharreguy B, Cuny E, Tignol J, Bioulac B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci. 2008;33(5):405\u201312.","journal-title":"J Psychiatry Neurosci"},{"issue":"6","key":"633_CR56","first-page":"563","volume":"3","author":"AL Thorsen","year":"2018","unstructured":"Thorsen AL, Hagland P, Radua J, Mataix-Cols D, Kvale G, Hansen B, et al. Emotional Processing in Obsessive-compulsive disorder: a systematic review and Meta-analysis of 25 functional neuroimaging studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(6):563\u201371.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"633_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.eurpsy.2017.08.001","volume":"46","author":"A Rasgon","year":"2017","unstructured":"Rasgon A, Lee WH, Leibu E, Laird A, Glahn D, Goodman W, et al. Neural correlates of affective and non-affective cognition in obsessive compulsive disorder: a meta-analysis of functional imaging studies. Eur Psychiatry. 2017;46:25\u201332.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"633_CR58","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.euroneuro.2015.12.033","volume":"26","author":"CM Gillan","year":"2016","unstructured":"Gillan CM, Robbins TW, Sahakian BJ, van den Heuvel OA, van Wingen G. The role of habit in compulsivity. Eur Neuropsychopharmacol. 2016;26(5):828\u201340.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2\u20133","key":"633_CR59","first-page":"267","volume":"21","author":"DJ Stein","year":"2006","unstructured":"Stein DJ, Arya M, Pietrini P, Rapoport JL, Swedo SE. Neurocircuitry of disgust and anxiety in obsessive-compulsive disorder: a positron emission tomography study. Metab Brain Dis. 2006;21(2\u20133):267\u201377.","journal-title":"Metab Brain Dis"},{"key":"633_CR60","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neubiorev.2021.06.022","volume":"128","author":"E Courtiol","year":"2021","unstructured":"Courtiol E, Menezes EC, Teixeira CM. Serotonergic regulation of the dopaminergic system: implications for reward-related functions. Neurosci Biobehav Rev. 2021;128:282\u201393.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"633_CR61","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0306-4522(97)00268-6","volume":"82","author":"C Peyron","year":"1998","unstructured":"Peyron C, Petit JM, Rampon C, Jouvet M, Luppi PH. Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience. 1998;82(2):443\u201368.","journal-title":"Neuroscience"},{"issue":"12","key":"633_CR62","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41386-019-0436-2","volume":"44","author":"M Kim","year":"2019","unstructured":"Kim M, Kwak S, Yoon YB, Kwak YB, Kim T, Cho KIK, et al. Functional connectivity of the raphe nucleus as a predictor of the response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Neuropsychopharmacology. 2019;44(12):2073\u201381.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"633_CR63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1515\/REVNEURO.2010.21.2.119","volume":"21","author":"S Nikolaus","year":"2010","unstructured":"Nikolaus S, Antke C, Beu M, M\u00fcller HW, Cortical GABA. Striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders\u2013results from in vivo imaging studies. Rev Neurosci. 2010;21(2):119\u201339.","journal-title":"Rev Neurosci"},{"issue":"8","key":"633_CR64","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/sj.npp.1301290","volume":"32","author":"W Zitterl","year":"2007","unstructured":"Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Schmidl-Mohl B, et al. [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology. 2007;32(8):1661\u20138.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"633_CR65","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1017\/S0033291715001865","volume":"46","author":"E Kim","year":"2016","unstructured":"Kim E, Howes OD, Park JW, Kim SN, Shin SA, Kim BH, et al. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11\u00a0C]DASB PET study. Psychol Med. 2016;46(2):357\u201366.","journal-title":"Psychol Med"},{"issue":"1","key":"633_CR66","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41598-018-37710-4","volume":"9","author":"KR M\u00fcller-Vahl","year":"2019","unstructured":"M\u00fcller-Vahl KR, Szejko N, Wilke F, Jakubovski E, Geworski L, Bengel F, et al. Serotonin transporter binding is increased in Tourette syndrome with obsessive compulsive disorder. Sci Rep. 2019;9(1):972.","journal-title":"Sci Rep"},{"issue":"12","key":"633_CR67","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/S0006-3223(03)00544-4","volume":"54","author":"HB Simpson","year":"2003","unstructured":"Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang DR, Abi-Dargham A, et al. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry. 2003;54(12):1414\u201321.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"633_CR68","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1017\/S1461145710001604","volume":"14","author":"S Hesse","year":"2011","unstructured":"Hesse S, Stengler K, Regenthal R, Patt M, Becker GA, Franke A, et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2011;14(5):606\u201317.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"633_CR69","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00702-007-0785-6","volume":"114","author":"M Reimold","year":"2007","unstructured":"Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11\u00a0C]DASB PET study. J Neural Transm (Vienna). 2007;114(12):1603\u20139.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"633_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuroimage.2009.07.069","volume":"49","author":"R Matsumoto","year":"2010","unstructured":"Matsumoto R, Ichise M, Ito H, Ando T, Takahashi H, Ikoma Y, et al. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11\u00a0C]DASB PET study. NeuroImage. 2010;49(1):121\u20136.","journal-title":"NeuroImage"},{"issue":"13","key":"633_CR71","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1038\/npp.2008.35","volume":"33","author":"W Zitterl","year":"2008","unstructured":"Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Wenzel T, et al. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology. 2008;33(13):3126\u201334.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"633_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11920-012-0268-9","volume":"14","author":"DJ Stein","year":"2012","unstructured":"Stein DJ, Koen N, Fineberg N, Fontenelle LF, Matsunaga H, Osser D, et al. A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep. 2012;14(3):211\u20139.","journal-title":"Curr Psychiatry Rep"},{"issue":"7 Suppl","key":"633_CR73","first-page":"5","volume":"164","author":"LM Koran","year":"2007","unstructured":"Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7 Suppl):5\u201353.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"633_CR74","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1037\/0735-7044.112.6.1475","volume":"112","author":"H Szechtman","year":"1998","unstructured":"Szechtman H, Sulis W, Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci. 1998;112(6):1475\u201385.","journal-title":"Behav Neurosci"},{"issue":"1","key":"633_CR75","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0165-1781(90)90151-T","volume":"33","author":"BG Borcherding","year":"1990","unstructured":"Borcherding BG, Keysor CS, Rapoport JL, Elia J, Amass J. Motor\/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res. 1990;33(1):83\u201394.","journal-title":"Psychiatry Res"},{"issue":"5","key":"633_CR76","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/YIC.0000000000000368","volume":"36","author":"JE Grant","year":"2021","unstructured":"Grant JE, Hook R, Valle S, Chesivoir E, Chamberlain SR. Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial. Int Clin Psychopharmacol. 2021;36(5):225\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"633_CR77","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00259-003-1245-7","volume":"30","author":"CH Kim","year":"2003","unstructured":"Kim CH, Koo MS, Cheon KA, Ryu YH, Lee JD, Lee HS. Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging. 2003;30(12):1637\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"633_CR78","doi-asserted-by":"crossref","unstructured":"Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65 Suppl 14:11\u2013\u20097.","DOI":"10.4088\/JCP.v65n0106"},{"issue":"12","key":"633_CR79","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1176\/appi.ajp.161.12.2201","volume":"161","author":"NJ van der Wee","year":"2004","unstructured":"van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, van Megen HJ, et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry. 2004;161(12):2201\u20136.","journal-title":"Am J Psychiatry"},{"key":"633_CR80","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/NDT.S211703","volume":"16","author":"S Karthik","year":"2020","unstructured":"Karthik S, Sharma LP, Narayanaswamy JC. Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 2020;16:1003\u201313.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"633_CR81","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1097\/01.chi.0000132812.44664.2d","volume":"43","author":"DR Rosenberg","year":"2004","unstructured":"Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1146\u201353.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"633_CR82","first-page":"S58","volume":"61","author":"K Sheshachala","year":"2019","unstructured":"Sheshachala K, Narayanaswamy JC. Glutamatergic augmentation strategies in obsessive-compulsive disorder. Indian J Psychiatry. 2019;61(Suppl 1):S58\u201365.","journal-title":"Indian J Psychiatry"},{"key":"633_CR83","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.neuropharm.2017.09.013","volume":"126","author":"JD Guo","year":"2017","unstructured":"Guo JD, O\u2019Flaherty BM, Rainnie DG. Serotonin gating of cortical and thalamic glutamate inputs onto principal neurons of the basolateral amygdala. Neuropharmacology. 2017;126:224\u201332.","journal-title":"Neuropharmacology"},{"key":"633_CR84","doi-asserted-by":"publisher","first-page":"1065812","DOI":"10.3389\/fpsyt.2023.1065812","volume":"14","author":"K Swierkosz-Lenart","year":"2023","unstructured":"Swierkosz-Lenart K, Dos Santos JFA, Elowe J, Clair AH, Bally JF, Riquier F, et al. Therapies for obsessive-compulsive disorder: current state of the art and perspectives for approaching treatment-resistant patients. Front Psychiatry. 2023;14:1065812.","journal-title":"Front Psychiatry"},{"key":"633_CR85","unstructured":"M\u0105czka G Psychoterapia poznawczo-behawioralna (CBT). 2021 [Access: 2023, July 17, https:\/\/www.centrumdobrejterapii.pl\/materialy\/psychoterapia-poznawczo-behawioralna-cbt\/]."},{"issue":"1","key":"633_CR86","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.psc.2022.10.004","volume":"46","author":"SD Spencer","year":"2023","unstructured":"Spencer SD, Stiede JT, Wiese AD, Goodman WK, Guzick AG, Storch EA. Cognitive-behavioral therapy for obsessive-compulsive disorder. Psychiatr Clin North Am. 2023;46(1):167\u201380.","journal-title":"Psychiatr Clin North Am"},{"issue":"8","key":"633_CR87","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/1570159X16666181026163922","volume":"17","author":"GD Kotzalidis","year":"2019","unstructured":"Kotzalidis GD, Del Casale A, Simmaco M, Pancheri L, Brugnoli R, Paolini M, et al. Placebo effect in obsessive-compulsive disorder (OCD). Placebo response and Placebo responders in OCD: the Trend Over Time. Curr Neuropharmacol. 2019;17(8):741\u201374.","journal-title":"Curr Neuropharmacol"},{"issue":"1\u20132","key":"633_CR88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0169-328X(96)00172-6","volume":"43","author":"AS Chang","year":"1996","unstructured":"Chang AS, Chang SM, Starnes DM, Schroeter S, Bauman AL, Blakely RD. Cloning and expression of the mouse serotonin transporter. Brain Res Mol Brain Res. 1996;43(1\u20132):185\u201392.","journal-title":"Brain Res Mol Brain Res"},{"issue":"6","key":"633_CR89","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nsmb.1602","volume":"16","author":"Z Zhou","year":"2009","unstructured":"Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol. 2009;16(6):652\u20137.","journal-title":"Nat Struct Mol Biol"},{"key":"633_CR90","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/7854_2020_204","volume":"49","author":"C Pittenger","year":"2021","unstructured":"Pittenger C. Pharmacotherapeutic strategies and new targets in OCD. Curr Top Behav Neurosci. 2021;49:331\u201384.","journal-title":"Curr Top Behav Neurosci"},{"issue":"4","key":"633_CR91","first-page":"533","volume":"13","author":"J Volpi-Abadie","year":"2013","unstructured":"Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533\u201340.","journal-title":"Ochsner J"},{"issue":"8","key":"633_CR92","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/archpsyc.1991.01810320054008","volume":"48","author":"Clomipramine in the","year":"1991","unstructured":"Clomipramine in the. Treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry. 1991;48(8):730\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"633_CR93","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","volume":"162","author":"EB Foa","year":"2005","unstructured":"Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151\u201361.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"633_CR94","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00131746-200005000-00002","volume":"6","author":"BA Fallon","year":"2000","unstructured":"Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract. 2000;6(3):113\u201328.","journal-title":"J Psychiatr Pract"},{"issue":"Suppl 1","key":"633_CR95","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.","journal-title":"BMC Psychiatry"},{"issue":"11","key":"633_CR96","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.4088\/JCP.v63n1108","volume":"63","author":"U Albert","year":"2002","unstructured":"Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002;63(11):1004\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"633_CR97","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4088\/JCP.v64n0508","volume":"64","author":"E Hollander","year":"2003","unstructured":"Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2003;64(5):546\u201350.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"633_CR98","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/0897190014521996","volume":"27","author":"G Bokor","year":"2014","unstructured":"Bokor G, Anderson PD. Obsessive-compulsive disorder. J Pharm Pract. 2014;27(2):116\u201330.","journal-title":"J Pharm Pract"},{"issue":"5","key":"633_CR99","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1176\/ajp.150.5.819","volume":"150","author":"TA Grady","year":"1993","unstructured":"Grady TA, Pigott TA, L\u2019Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993;150(5):819\u201321.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"633_CR100","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1176\/ajp.150.4.647","volume":"150","author":"CJ McDougle","year":"1993","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993;150(4):647\u20139.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"633_CR101","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00004714-199202000-00003","volume":"12","author":"TA Pigott","year":"1992","unstructured":"Pigott TA, L\u2019Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12(1):11\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"633_CR102","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/0976-500X.149144","volume":"6","author":"SA Sassano-Higgins","year":"2015","unstructured":"Sassano-Higgins SA, Pato MT. Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: a meta-analysis. J Pharmacol Pharmacother. 2015;6(1):36\u20138.","journal-title":"J Pharmacol Pharmacother"},{"issue":"2","key":"633_CR103","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/hup.2461","volume":"30","author":"D Serata","year":"2015","unstructured":"Serata D, Kotzalidis GD, Rapinesi C, Janiri D, Di Pietro S, Callovini G, et al. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol. 2015;30(2):70\u201384.","journal-title":"Hum Psychopharmacol"},{"issue":"10","key":"633_CR104","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.4088\/JCP.v65n1015","volume":"65","author":"S Pallanti","year":"2004","unstructured":"Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry. 2004;65(10):1394\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"633_CR105","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4088\/JCP.v66n0415","volume":"66","author":"LM Koran","year":"2005","unstructured":"Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005;66(4):515\u201320.","journal-title":"J Clin Psychiatry"},{"key":"633_CR106","doi-asserted-by":"crossref","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update Meta-analysis of Double-Blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015;18(9).","DOI":"10.1093\/ijnp\/pyv047"},{"key":"633_CR107","doi-asserted-by":"publisher","first-page":"112602","DOI":"10.1016\/j.psychres.2019.112602","volume":"282","author":"A Modarresi","year":"2019","unstructured":"Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602.","journal-title":"Psychiatry Res"},{"key":"633_CR108","doi-asserted-by":"crossref","unstructured":"Andrade C. Augmentation with Memantine in Obsessive-compulsive disorder. J Clin Psychiatry. 2019;80(6).","DOI":"10.4088\/JCP.19f13163"},{"issue":"3","key":"633_CR109","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","volume":"72","author":"J Kryst","year":"2020","unstructured":"Kryst J, Kawalec P, Mitoraj AM, Pilc A, Laso\u0144 W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72(3):543\u201362.","journal-title":"Pharmacol Rep"},{"issue":"11","key":"633_CR110","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","volume":"9","author":"SY Smith-Apeldoorn","year":"2022","unstructured":"Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9(11):907\u201321.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"633_CR111","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an International Expert Opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383\u201399.","journal-title":"Am J Psychiatry"},{"key":"633_CR112","doi-asserted-by":"crossref","unstructured":"Martinotti G, Chiappini S, Pettorruso M, Mosca A, Miuli A, Di Carlo F et al. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sci. 2021;11(7).","DOI":"10.3390\/brainsci11070856"},{"issue":"12","key":"633_CR113","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"CI Rodriguez","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475\u201383.","journal-title":"Neuropsychopharmacology"},{"key":"633_CR114","unstructured":"Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. National Library of Medicine (US). 2018, November 13\u20132024, December 15 [ClinicalTrials.gov. Identifier NCT03356483, Access: 2024, April 15, https:\/\/clinicaltrials.gov\/study\/NCT03356483]."},{"key":"633_CR115","unstructured":"Psilocybin for Treatment of Obsessive Compulsive Disorder. National Library of Medicine (US). 2019, January 02\u20132023, December 30 [ClinicalTrials.gov Identifier NCT03300947, Access: 2024, April 15, https:\/\/clinicaltrials.gov\/study\/NCT03300947]."},{"key":"633_CR116","unstructured":"PsilOCD: A Pharmacological-Challenge Feasibility Study. National Library of Medicine (US). 2022, October 28\u20132024, July 30 [ClinicalTrials.gov. Identifier NCT06258031, Access: 2024, April 15, https:\/\/clinicaltrials.gov\/study\/NCT06258031]."},{"key":"633_CR117","unstructured":"Effects of Psilocybin in Obsessive Compulsive Disorder. National Library of Medicine (US). 2022, November 28\u20132026, September 12 [ClinicalTrials.gov. Identifier NCT05546658, Access: 2024, April 15, https:\/\/clinicaltrials.gov\/study\/NCT05546658]."},{"key":"633_CR118","unstructured":"Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD. National Library of Medicine (US). 2023, May 01\u20132025, December 01 [ClinicalTrials.gov. Identifier NCT04882839, Access: 2024, April 15, https:\/\/clinicaltrials.gov\/study\/NCT04882839]."},{"key":"633_CR119","unstructured":"Effects of Repeated Psilocybin Dosing in OCD. National Library of Medicine (US). 2023, July 20\u20132027, July [ClinicalTrials.gov. Identifier NCT05370911, Access: 2024, April 15, https:\/\/clinicaltrials.gov\/study\/NCT05370911]."},{"key":"633_CR120","unstructured":"Feasibility C, Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD. National Library of Medicine (US).; 2024, April\u2013\u20092024, September [ClinicalTrials.gov. Identifier NCT06299319, Access: 2024, April 15, https:\/\/clinicaltrials.gov\/study\/NCT06299319]."},{"issue":"20","key":"633_CR121","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1016\/j.bmcl.2005.06.104","volume":"15","author":"H Sard","year":"2005","unstructured":"Sard H, Kumaran G, Morency C, Roth BL, Toth BA, He P, et al. SAR of psilocybin analogs: discovery of a selective 5-HT 2\u00a0C agonist. Bioorg Med Chem Lett. 2005;15(20):4555\u20139.","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"633_CR122","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1271\/bbb.90095","volume":"73","author":"Y Matsushima","year":"2009","unstructured":"Matsushima Y, Shirota O, Kikura-Hanajiri R, Goda Y, Eguchi F. Effects of Psilocybe argentipes on marble-burying behavior in mice. Biosci Biotechnol Biochem. 2009;73(8):1866\u20138.","journal-title":"Biosci Biotechnol Biochem"},{"issue":"1","key":"633_CR123","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41398-023-02456-9","volume":"13","author":"S Singh","year":"2023","unstructured":"Singh S, Botvinnik A, Shahar O, Wolf G, Yakobi C, Saban M, et al. Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder. Transl Psychiatry. 2023;13(1):164.","journal-title":"Transl Psychiatry"},{"key":"633_CR124","doi-asserted-by":"publisher","first-page":"113093","DOI":"10.1016\/j.bbr.2020.113093","volume":"401","author":"AU Odland","year":"2021","unstructured":"Odland AU, Kristensen JL, Andreasen JT. Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice. Behav Brain Res. 2021;401:113093.","journal-title":"Behav Brain Res"},{"issue":"2","key":"633_CR125","first-page":"509","volume":"117","author":"J Delay","year":"1959","unstructured":"Delay J, Pichot P, Lemperiere T, Quetin AM. [Therapeutic effect of psilocybin on convulsive neurosis]. Ann Med Psychol (Paris). 1959;117(2):509\u201315.","journal-title":"Ann Med Psychol (Paris)"},{"issue":"9","key":"633_CR126","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1176\/ajp.144.9.1239b","volume":"144","author":"HL Leonard","year":"1987","unstructured":"Leonard HL, Rapoport JL. Relief of obsessive-compulsive symptoms by LSD and psilocin. Am J Psychiatry. 1987;144(9):1239\u201340.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"633_CR127","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1176\/ajp.154.7.1037b","volume":"154","author":"FA Moreno","year":"1997","unstructured":"Moreno FA, Delgado PL. Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry. 1997;154(7):1037\u20138.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"633_CR128","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1176\/ajp.156.7.1123","volume":"156","author":"DM Perrine","year":"1999","unstructured":"Perrine DM. Hallucinogens and obsessive-compulsive disorder. Am J Psychiatry. 1999;156(7):1123.","journal-title":"Am J Psychiatry"},{"key":"633_CR129","doi-asserted-by":"publisher","first-page":"1178529","DOI":"10.3389\/fpsyt.2023.1178529","volume":"14","author":"THW Ching","year":"2023","unstructured":"Ching THW, Grazioplene R, Bohner C, Kichuk SA, DePalmer G, D\u2019Amico E, et al. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front Psychiatry. 2023;14:1178529.","journal-title":"Front Psychiatry"},{"key":"633_CR130","doi-asserted-by":"publisher","first-page":"1278823","DOI":"10.3389\/fpsyt.2023.1278823","volume":"14","author":"THW Ching","year":"2023","unstructured":"Ching THW, Amoroso L, Bohner C, D\u2019Amico E, Eilbott J, Entezar T, et al. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Front Psychiatry. 2023;14:1278823.","journal-title":"Front Psychiatry"},{"issue":"1","key":"633_CR131","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187.","journal-title":"Sci Rep"},{"key":"633_CR132","doi-asserted-by":"publisher","first-page":"120414","DOI":"10.1016\/j.neuroimage.2023.120414","volume":"283","author":"S Delli Pizzi","year":"2023","unstructured":"Delli Pizzi S, Chiacchiaretta P, Sestieri C, Ferretti A, Tullo MG, Della Penna S, et al. LSD-induced changes in the functional connectivity of distinct thalamic nuclei. NeuroImage. 2023;283:120414.","journal-title":"NeuroImage"},{"issue":"9","key":"633_CR133","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 2017;31(9):1091\u2013120.","journal-title":"J Psychopharmacol"},{"key":"633_CR134","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/7854_2017_479","volume":"36","author":"DA Martin","year":"2018","unstructured":"Martin DA, Nichols CD. The effects of Hallucinogens on Gene expression. Curr Top Behav Neurosci. 2018;36:137\u201358.","journal-title":"Curr Top Behav Neurosci"},{"key":"633_CR135","doi-asserted-by":"publisher","first-page":"1391412","DOI":"10.3389\/fphar.2024.1391412","volume":"15","author":"E Lerer","year":"2024","unstructured":"Lerer E, Botvinnik A, Shahar O, Grad M, Blakolmer K, Shomron N, et al. Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators. Front Pharmacol. 2024;15:1391412.","journal-title":"Front Pharmacol"},{"key":"633_CR136","doi-asserted-by":"publisher","first-page":"1156319","DOI":"10.3389\/fnins.2023.1156319","volume":"17","author":"MM Urban","year":"2023","unstructured":"Urban MM, Stingl MR, Meinhardt MW. Mini-review: the neurobiology of treating substance use disorders with classical psychedelics. Front Neurosci. 2023;17:1156319.","journal-title":"Front Neurosci"},{"key":"633_CR137","doi-asserted-by":"publisher","first-page":"1104627","DOI":"10.3389\/fpsyg.2023.1104627","volume":"14","author":"J K\u00e4h\u00f6nen","year":"2023","unstructured":"K\u00e4h\u00f6nen J. Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences. Front Psychol. 2023;14:1104627.","journal-title":"Front Psychol"},{"issue":"3","key":"633_CR138","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a Unified Model of the Brain Action of Psychedelics. Pharmacol Rev. 2019;71(3):316\u201344.","journal-title":"Pharmacol Rev"},{"key":"633_CR139","doi-asserted-by":"crossref","unstructured":"Acevedo EC, Uhler S, White KP, Al-Shawaf L. What predicts beneficial outcomes in psychedelic use? A Quantitative Content Analysis of Psychedelic Health Outcomes. J Psychoact Drugs. 2024:1\u201310.","DOI":"10.1080\/02791072.2024.2314729"},{"issue":"4","key":"633_CR140","doi-asserted-by":"publisher","first-page":"e245960","DOI":"10.1001\/jamanetworkopen.2024.5960","volume":"7","author":"A Yerubandi","year":"2024","unstructured":"Yerubandi A, Thomas JE, Bhuiya N, Harrington C, Villa Zapata L, Caballero J. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and Meta-analysis. JAMA Netw Open. 2024;7(4):e245960.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"633_CR141","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","volume":"75","author":"A Ws\u00f3\u0142","year":"2023","unstructured":"Ws\u00f3\u0142 A. Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacol Rep. 2023;75(6):1362\u201380.","journal-title":"Pharmacol Rep"},{"issue":"2","key":"633_CR142","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172(2):145\u201356.","journal-title":"Psychopharmacology"},{"key":"633_CR143","doi-asserted-by":"publisher","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","volume":"13","author":"CA MacCallum","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217.","journal-title":"Front Psychiatry"},{"issue":"4","key":"633_CR144","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/02791072.2021.1983673","volume":"54","author":"CM Fitzpatrick","year":"2022","unstructured":"Fitzpatrick CM, Anderson BT, Agin-Liebes G, Guydish J. Comment and response: (Lugo-Radillo & Cortez-Lopez, 2020) long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J Psychoact Drugs. 2022;54(4):324\u20137.","journal-title":"J Psychoact Drugs"},{"key":"633_CR145","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/7854_2016_457","volume":"36","author":"JH Halpern","year":"2018","unstructured":"Halpern JH, Lerner AG, Passie T. A review of Hallucinogen Persisting Perception Disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Curr Top Behav Neurosci. 2018;36:333\u201360.","journal-title":"Curr Top Behav Neurosci"},{"key":"633_CR146","doi-asserted-by":"publisher","first-page":"173129","DOI":"10.1016\/j.pbb.2021.173129","volume":"203","author":"MLS Bates","year":"2021","unstructured":"Bates MLS, Trujillo KA. Use and abuse of dissociative and psychedelic drugs in adolescence. Pharmacol Biochem Behav. 2021;203:173129.","journal-title":"Pharmacol Biochem Behav"},{"key":"633_CR147","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jad.2023.01.077","volume":"326","author":"NL Modlin","year":"2023","unstructured":"Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-Jones M, Schlosser D, et al. Optimizing outcomes in psilocybin therapy: considerations in participant evaluation and preparation. J Affect Disord. 2023;326:18\u201325.","journal-title":"J Affect Disord"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00633-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-024-00633-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00633-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T01:05:43Z","timestamp":1726016743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-024-00633-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":147,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1007\/s43440-024-00633-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}